MD Anderson Research Highlights for February 23, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic,...
Newly developed radio-labeled molecule enables real-time...
Researchers at The University of Texas MD Anderson Cancer Center have developed a new radio-labeled molecule capable of selectively...
MD Anderson receives over $31 million in CPRIT funding
The University of Texas MD Anderson Cancer Center was awarded $31.73 million from the Cancer Prevention and Research Institute of...
MD Anderson renews partnership with Banner Health
The University of Texas MD Anderson Cancer Center announced today its first-ever partnership renewal with Banner Health, which created...
MD Anderson Research Highlights for February 9, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic,...
MD Anderson honors World Cancer Day, reinforces commitment...
The University of Texas MD Anderson Cancer Center celebrates World Cancer Day, Feb. 4, in honor of the global initiative to end cancer.
Trametinib represents potential new standard-of-care for...
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the...